Document is current
Any future updates will be listed below
-
Authors
Uijttewaal, Esther C. H. https://orcid.org/0000-0003-3892-2820
Lee, Joonsun
Sell, Annika Charlotte https://orcid.org/0009-0006-2272-0094
Botay, Naomi https://orcid.org/0009-0001-5469-1252
Vainorius, Gintautas
Novatchkova, Maria
Baar, Juliane
Yang, Jiaye
Potzler, Tobias
van der Leij, Sophie
Lowden, Christopher https://orcid.org/0000-0002-1839-164X
Sinner, Julia
Elewaut, Anais https://orcid.org/0009-0009-4064-7320
Gavrilovic, Milanka
Obenauf, Anna https://orcid.org/0000-0002-9556-5914
Schramek, Daniel https://orcid.org/0000-0001-9977-2104
Elling, Ulrich https://orcid.org/0000-0002-4514-2809
-
Funding
Funding for this research was provided by:
Terry Fox Research Institute (TFRI Project #1107)
Krembil Foundation
Canada Research Chairs
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 19 November 2024
First Online: 16 December 2024
Competing interests
: E.U., A.S. and U.E. are listed as inventors of EP3889259A1, and U.E. is listed as inventor of EP3219799A1. D.S. and U.E. are co-founders of Viverita Therapeutics and consultants to Tango Therapeutics. The other authors declare no competing interests.
